Primary Amine Aldehyde Scavenging for MDA and HNE Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments have not effectively addressed the pathogenic effects of toxic aldehydes such as malondialdehyde (MDA) and 4-hydroxyl-2-nonenal (HNE) in various diseases and disorders, including ocular and skin conditions, leading to aldehyde-mediated damage and inflammation.
Innovation Solution
Administration of primary amine compounds that form Schiff base condensations with MDA and HNE, forming closed-ring structures to trap and eliminate these aldehydes, thereby reducing their harmful effects on proteins, lipids, and DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used, then general disease management is provided, but toxic aldehyde-mediated damage and inflammation are not effectively addressed
Solution Approach 1:
The patent introduces primary amine compounds as intermediary substances that specifically bind to toxic aldehydes (MDA and HNE) through Schiff base condensation. These compounds act as mediators between the toxic aldehydes and the body's defense mechanisms, forming closed-ring structures that trap and eliminate the aldehydes, thereby protecting proteins, lipids, and DNA from aldehyde-mediated damage.
Solution Approach 2:
The patent converts the harmful reactive nature of toxic aldehydes into a beneficial therapeutic effect. By utilizing the aldehydes' tendency to form Schiff base condensations, the invention directs this reactive property toward forming harmless closed-ring structures with primary amine compounds, thereby eliminating the toxic effects while leveraging the chemical reactivity for therapeutic benefit.
2Object-affected harmful factors
If primary amine compounds are administered to scavenge aldehydes, then aldehyde concentrations decrease significantly, but new therapeutic compounds are required
Solution Approach 1:
The patent modifies the chemical parameters of existing primary amine compounds to optimize their aldehyde-scavenging properties. By adjusting parameters such as the pKa of the primary amine group and the molecular structure, the invention creates compounds with enhanced ability to form stable closed-ring structures with toxic aldehydes, thereby improving scavenging efficiency while working within available compound frameworks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The primary amine compounds effectively scavenge and trap MDA and HNE, decreasing their concentrations by up to 90% and reducing aldehyde-mediated cell death and inflammation, thus treating and preventing associated diseases and disorders.
Implementation Method 1
Administration of primary amine compounds that form Schiff base condensations with MDA and HNE, forming closed-ring structures to trap and eliminate these aldehydes
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.